Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies.

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

RTW Investments

Cormorant Asset Management

Fidelity

Google Ventures

New Enterprise Associates

Cambridge Asset Management

Casdin Capital

HBM Healthcare Investments AG

Fidelity Management and Research Company

Aisling Capital

Amzak Health Investors

Avoro Capital Advisors

Today we share our second quarter 2024 financial results and corporate update. View the full press release here: https://bit.ly/3WDjih9

Step into the future with Monte Rosa's dynamic Data Sciences team! #DataSciences #AI #Biotech

We’re pleased to share this brand new scientific review of VAV1 published in Trends in Immunology, highlighting the therapeutic potential of novel approaches targeting VAV1 for autoimmune diseases, including our VAV1 molecular glue degrader MRT-6160. 

Read the scientific review here: https://bit.ly/4c6BO6Z

Every year Monte Rosa welcomes the brilliant scientists of tomorrow. Their curiosity, innovation, and enthusiasm help shape our culture. Learn more about the Monte Rosa Internship experience. #NationalInternDay #Biotech

Starting off the summer with good times and great people. 
#Summer #GoodTimes

Join our CEO Markus Warmuth next week for a fireside chat at the virtual UBS TPD day. Learn more here: https://bit.ly/3zuVS5I

COM:MONTEROSATX